logo-loader

Arecor

Receive alerts
Market:
Unlisted (UK)
Market Cap:
-
Price
-
Change
-
52 weeks high
-
52 weeks low
-

Arecor is leveraging this platform to (i) develop a portfolio of proprietary products for diabetes care and (ii) deliver superior reformulations of its partners proprietary products.

Proprietary Product Development

Arecor is committed to leveraging its ArestatTM platform to develop a portfolio of proprietary products enabling improved treatment for diabetes care via the innovative reformulations of approved proteins and peptides.

View our product overview

Technology Partnering

Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would simply not be possible using conventional formulation science.

PARTNER WITH US

 

United Kingdom.

Board of Directors

Sarah Howell, Ph.D., Chief Executive Officer

Sarah, who joined Arecor in 2013, before being appointed Chief Executive Officer to the Group in 2015, has a strong background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of product types and therapeutic areas. She has served in a number of leading roles in the pharmaceutical industry, most recently as Vice President for CMC (Chemistry, Manufacturing & Controls) and Technical Development for BTG where she had full responsibility for CMC development and supply across BTG’s diverse portfolio of clinical and commercial products. 

Previously she held senior roles in product development and manufacturing for UCB-Celltech and GlaxoSmithKline. She is also an active member of the BioIndustry Association (BIA) Manufacturing Advisory Committee.

Sarah has an honours degree in Chemistry from the University of Birmingham and a Ph.D. in Physical Organic Chemistry from the University of St Andrews.

Andrew J M Richards, Ph.D., CBE (Chairman)

Andy is an established biotechnology entrepreneur and investor with broad experience from the UK biotechnology sector in research, drug development, commercial deals and scaling up companies. He is the Chairman of Congenica Ltd, Abcodia Ltd, and a director of Silence Therapeutics plc, Sensiia Ltd, and Ieso Digital Health Ltd. He is Chairman of BBT the Babraham Research Campus and a director of Cancer Research Technology Ltd (the commercial arm of Cancer Research UK).

Andy is a Cambridge graduate with a Ph.D. in enzyme chemistry and was a founder of Chiroscience in 1992 and an Executive Director through to the Celltech deal in 1999. Andy has a track record as a founder, active investor in and director of more than 25 innovative healthcare and life-science companies, including Vectura plc and Arakis Ltd.

Susan Lowther, Chief Financial Officer and Company Secretary

Susan joined Arecor in 2019 as Chief Financial Officer and Company Secretary.  She has significant experience of the life science industry, growing companies and executing M&A transactions.  She also has a strong commercial and operational background, with direct responsibility for finance, HR, IT and facilities functions.

Susan’s experience as a Chief Financial Officer includes both public and private companies; IXICO plc, Novacyt SA, BioWisdom Ltd and RiboTargets Ltd.

Sam Fazeli, Ph.D., Non-Executive Director

Sam has served as a member of our Board of Directors since September 2017 and he brings over nineteen years of experience of conducting equity research as a pharmaceutical analyst, working at firms such as Nomura International and HSBC. Currently, he is Director of EMEA Research and Senior Pharmaceutical Analyst at Bloomberg Intelligence in London, where he specialises in global pharmaceuticals.

Prior to joining Bloomberg in 2010, Sam worked at Piper Jaffray, Ltd. as a pharmaceutical analyst and head of European research. Before transitioning to investment banking, he was a research scientist for seven years. Sam has been ranked a top analyst by both the UK and Pan-European Extel surveys. He received a first degree from Cardiff University, and a Ph.D. in pharmacology from the University of London.

Andrew Lane, MA, Non-Executive Director

Andrew joined Unilever as a marketing trainee in 1985 after studying Biochemistry at Cambridge University. He is a founding Director of Unilever Ventures which focuses on investments in Home and Personal Care Technology.

He has been involved as a Director in the set-up and development of three other life science businesses (BAC BV, Pharmakodex Ltd, and Insense Ltd).

Alan E Smith, Ph.D., FRS, CBE, Non-Executive Director

Alan is the former Senior Vice President and the Chief Scientific Officer of Genzyme Corporation, Cambridge MA, where he had overall responsibility for the company’s science. Prior to its acquisition by Genzyme in 1989, Alan was the vice president and scientific director of Integrated Genetics, a MA start-up biotechnology company. From 1980-84 he was head of the biochemistry division at the National Institute of Medical Research, Mill Hill, London. Presently, Alan sits on the Scientific Advisory Boards of: The Cancer Research Institute in Cambridge UK; Pharnext – a start-up genomics company in Paris, France; and ImmuneXcite – a start-up immunology company, in Lexington MA. He is on the Board of Directors of Advantagene – a start-up gene therapy company in Newton MA.

He is chairman of the Board of Cambridge in America, the representative body of the University and Colleges of Cambridge in North America. Alan has published extensively on the genetic code and protein synthesis, tumour virology, cell biology and cystic fibrosis. He holds a B.A. from Christ’s College, Cambridge and a Ph.D. from the Laboratory of Molecular Biology, Cambridge, England. He is a fellow of the Royal Society of London and of Christ’s College.

Jeremy Curnock-Cook, Non-Executive Director

Jeremy is passionate about investing today for a healthier tomorrow and bringing tangible benefits to people across the world.

As a veteran in the life sciences/healthcare industry he has been actively supporting the commercialisation of healthcare innovations and helping entrepreneurs build their international businesses over the past 35 years.

Jeremy is passionate about investing today for a healthier tomorrow and bringing tangible benefits to people across the world.

As a veteran in the life sciences/healthcare industry he has been actively supporting the commercialisation of healthcare innovations and helping entrepreneurs build their international businesses over the past 35 years.

Founder and Managing Director of BioScience Managers, Jeremy brings his decades of international experience to our investment team, to support the identification of investment opportunities and in the strategic assessment of value creation options, in particular through M&A and expansion into new geographies. He actively supports portfolio companies through his executive and non-executive roles.

Over his career, Jeremy has successfully managed in excess of US$1billion in equity investments. He launched the first dedicated biotechnology fund for the Australian market and is a former head of the life science private equity team at Rothschild Asset Management, an early pioneer and significant investor in the sector. In his early career he founded the International Biochemicals Group which he successfully sold to Royal Dutch Shell. He has served on more than 40 boards of directors in the life science sector, in the UK, Europe, USA, Canada, Japan and Australia.

Jeremy received his MA in Natural Sciences from Trinity College in Dublin and was a research scientist at the Institute of Cancer Research from 1972 to 1973.

Alexander Crawford MA FCA, Non-Executive Director

Alexander joined Calculus Capital in 2015 as an Investment Director, and has over 20 years’ investment and corporate finance -experience, including senior roles in JP Morgan and Evercore Partners in London, New York and Johannesburg. He has an MA in Mathematics from Cambridge University and qualified as a Chartered Accountant with KPMG.

Alexander joined Calculus Capital in 2015 as an Investment Director, and has over 20 years’ investment and corporate finance -experience, including senior roles in JP Morgan and Evercore Partners in London, New York and Johannesburg. He has an MA in Mathematics from Cambridge University and qualified as a Chartered Accountant with KPMG.

He manages a number of Calculus Capital’s unlisted and listed life sciences investments, including sitting as observer on the board of Synpromics, which creates synthetic promoters for gene therapies.  He also sits as director or observer on the boards of Blu Wireless Technology, Weeding Technologies and Every1Mobile.

Address

Arecor Limited,
Chesterford Research Park
Little Chesterford
CB10 1XL
United Kingdom

Telephone: +44 1223 426 060
Email: [email protected]

Scientific Advisory Board

Arecor is honored to have the support of a world class Global Diabetes Scientific Advisory Board to support the scientific, pre-clinical and clinical development of its proprietary superior diabetes products to better improve the quality of life of those living with diabetes. The SAB brings together three world-renowned scientists and endocrinologists from the US and EU with extensive expertise in the field of diabetes and related conditions.

 

Bruce Buckingham, MD

Dr. Bruce Buckingham has served as a member of our Scientific Advisory Board since September 2017. He is Professor of Paediatrics (Endocrinology) at the Lucile Salter Packard Children’s Hospital, Stanford University School of Medicine. Dr. Buckingham’s major interest is in type 1 diabetes mellitus, continuous glucose sensor, and the development of an artificial pancreas.

His other research interests include using continuous glucose monitoring and algorithms to control blood glucose levels in intensive care units. He is currently working on the clinical trial: Accelerometer Use in the Prevention of Exercise-Associated Hypoglycemia in Type 1 Diabetes.

 

Eda Cengiz, MD

Dr. Eda Cengiz has served as a member of our Scientific Advisory Board since September 2017. She is Associate Professor of Paediatrics (Endocrinology) at the Yale School of Medicine, Yale University and is also a Fellow of Brown Medical School / Hasbro Children’s Hospital and an Elected Board Member (2016) of the International Society for Paediatric and Adolescent Diabetes. 

Dr. Cengiz’s prospectively designed clinical study (Early Cardiovascular Disease Markers for Children with Type 1 Diabetes (Jerusalem, Israel) (2009-2012), investigates signs of early cardiovascular disease in children with type 1 diabetes in the US and in Israel.

 

Thomas R. Pieber, MD

Dr. Thomas Pieber has served as a member of our Scientific Advisory Board since September 2017. He is a clinical specialist in endocrinology and diabetes mellitus, whose research is dedicated to the relationship of inflammation, energy homeostasis and human diseases. His group has developed a novel technique called open-flow microperfusion (OFM) which is used to explore energy metabolism in adipose and muscle tissue in diabetes.

Recently Dr. Pieber’s research has also addressed the role of 15-hydroxy-vitamin D in immune tolerance and autoimmunity. In a joint research effort with leading obesity centres in Europe, his group currently addresses the role of immune competent cells and novel pathways of chronic inflammation in obesity and diabetes. Dr. Pieber is Chairman of the Division of Endocrinology and Metabolism at the Medical University of Graz.